Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Reduce” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned an average recommendation of “Reduce” from the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $38.9167.

A number of brokerages have recently weighed in on HIMS. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Truist Financial lowered their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $54.38, for a total value of $143,400.06. Following the completion of the transaction, the insider owned 161,130 shares in the company, valued at approximately $8,762,249.40. This represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $8,581,970. This represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,561,799 shares of company stock worth $80,686,085. 13.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after buying an additional 227 shares in the last quarter. GAMMA Investing LLC raised its holdings in Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares in the last quarter. Bessemer Group Inc. raised its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares in the last quarter. True Vision MN LLC lifted its position in Hims & Hers Health by 3.6% in the second quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after purchasing an additional 328 shares during the period. Finally, Allworth Financial LP boosted its stake in Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after purchasing an additional 334 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $49.77 on Friday. The firm has a market cap of $11.25 billion, a PE ratio of 62.21, a price-to-earnings-growth ratio of 3.40 and a beta of 2.25. The firm’s 50-day simple moving average is $51.01 and its 200-day simple moving average is $48.89. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health has a 1 year low of $18.33 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter last year, the business posted $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.